Pacira BioSciences (NASDAQ:PCRX) Downgraded by Wall Street Zen to Buy

Pacira BioSciences (NASDAQ:PCRX) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

PCRX has been the subject of a number of other research reports. Barclays started coverage on shares of Pacira BioSciences in a report on Tuesday, December 9th. They issued an “equal weight” rating and a $27.00 price target for the company. Weiss Ratings restated a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. Truist Financial reduced their price target on shares of Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Friday, November 7th. HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of Pacira BioSciences in a research note on Friday, January 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Pacira BioSciences in a research note on Friday, January 9th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $30.75.

Pacira BioSciences Stock Down 3.0%

Pacira BioSciences stock opened at $21.91 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 5.26 and a quick ratio of 3.78. Pacira BioSciences has a 1-year low of $18.80 and a 1-year high of $27.64. The company has a market cap of $942.57 million, a PE ratio of 146.07 and a beta of 0.24. The stock’s 50 day moving average price is $22.65 and its 200 day moving average price is $23.85.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.28). Pacira BioSciences had a return on equity of 10.16% and a net margin of 0.97%.The business had revenue of $196.87 million during the quarter, compared to analysts’ expectations of $201.93 million. During the same quarter in the previous year, the company posted $0.91 EPS. The company’s revenue was up 5.1% compared to the same quarter last year. On average, sell-side analysts predict that Pacira BioSciences will post 2.41 EPS for the current fiscal year.

Insider Activity at Pacira BioSciences

In related news, CFO Shawn Cross sold 9,104 shares of the company’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $25.14, for a total value of $228,874.56. Following the sale, the chief financial officer owned 56,250 shares of the company’s stock, valued at approximately $1,414,125. This represents a 13.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Lauren Riker sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $20.81, for a total value of $83,240.00. Following the completion of the sale, the senior vice president directly owned 52,313 shares in the company, valued at approximately $1,088,633.53. The trade was a 7.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 30,416 shares of company stock worth $744,315 over the last quarter. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Pacira BioSciences

A number of institutional investors have recently made changes to their positions in the stock. Hussman Strategic Advisors Inc. purchased a new stake in Pacira BioSciences in the 3rd quarter valued at about $2,706,000. Doma Perpetual Capital Management LLC boosted its position in shares of Pacira BioSciences by 49.7% in the third quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company’s stock worth $69,613,000 after acquiring an additional 897,255 shares during the last quarter. Exchange Traded Concepts LLC purchased a new stake in Pacira BioSciences in the third quarter valued at approximately $1,948,000. Impax Asset Management Group plc increased its position in Pacira BioSciences by 27.7% during the third quarter. Impax Asset Management Group plc now owns 600,027 shares of the company’s stock worth $15,463,000 after purchasing an additional 130,000 shares during the last quarter. Finally, American Century Companies Inc. increased its position in Pacira BioSciences by 77.2% during the second quarter. American Century Companies Inc. now owns 1,182,513 shares of the company’s stock worth $28,262,000 after purchasing an additional 515,090 shares during the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Record EXPAREL sales — Pacira said EXPAREL delivered its strongest fourth-quarter performance in three years, driven by 7% volume growth, signaling solid demand for its core product. GlobeNewswire Release
• Neutral Sentiment: Company provided FY-2026 revenue guidance of $745.0 million to $770.0 million (versus consensus ~$766.9M); range implies growth but sits slightly below the consensus midpoint, leaving interpretation mixed for investors. Guidance Detail
• Neutral Sentiment: Full earnings materials and call resources are available (earnings press release, slide deck and call transcripts), useful for investors wanting management commentary on margin drivers and expense cadence. Slide Deck Earnings Call Transcript
• Negative Sentiment: Earnings and revenue missed estimates — Pacira reported Q4 EPS of $0.57 vs. consensus $0.85 and revenue of $196.9M vs. $201.9M expected; the EPS shortfall and top-line miss are primary drivers of the negative price reaction. MarketBeat Earnings Summary
• Negative Sentiment: Rising expenses pressured margins — management flagged higher operating costs that reduced net income and contributed to the EPS miss, raising near-term profitability concerns. Zacks Coverage

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.